VivoSeq
Nephrology

X-Linked Alport Syndrome

1

Pipeline Programs↗

0

Active Trials↗

1

Companies Involved↗

X-linked Alport syndrome is an early-stage landscape with 1 program across 1 company. The most active players are Novartis.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 21

Hydroxychloroquine Sulfate

Novartis

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

1

clinical trials

Completed1 · 100%

Clinical Trials

Trial Activity

Study of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS)
Completed·SShanghai Children's Hospital·Phase 2·NCT04937907·50 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)